Compare EVTC & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTC | OLMA |
|---|---|---|
| Founded | 1988 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2013 | 2020 |
| Metric | EVTC | OLMA |
|---|---|---|
| Price | $28.78 | $14.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $35.80 | ★ $45.50 |
| AVG Volume (30 Days) | 493.7K | ★ 1.6M |
| Earning Date | 05-06-2026 | 03-16-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ 27.17 | 15.00 |
| EPS | ★ 2.20 | N/A |
| Revenue | ★ $453,869,000.00 | N/A |
| Revenue This Year | $10.86 | N/A |
| Revenue Next Year | $6.78 | $347.28 |
| P/E Ratio | $13.05 | ★ N/A |
| Revenue Growth | ★ 11.48 | N/A |
| 52 Week Low | $24.95 | $2.86 |
| 52 Week High | $38.56 | $36.26 |
| Indicator | EVTC | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 53.00 | 27.11 |
| Support Level | $27.99 | $4.35 |
| Resistance Level | $30.42 | $27.38 |
| Average True Range (ATR) | 1.18 | 1.39 |
| MACD | 0.19 | -0.59 |
| Stochastic Oscillator | 59.86 | 2.98 |
Evertec Inc is a transaction processing business in Latin America and the Caribbean. Its business segments are Merchant Acquiring, Payment Services - Puerto Rico & Caribbean, Latin America Payments and Solutions, and Business Solutions which derive maximum revenue. The company serves a diversified customer base of financial institutions, merchants, corporations, and government agencies with mission-critical technology solutions that enable them to issue, process, and accept transactions securely. It derives maximum revenue from Latin America Payments and Solutions. Geographically, it operates in Puerto Rico, Caribbean, and Latin America.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.